{"id":910363,"date":"2025-11-14T17:11:20","date_gmt":"2025-11-14T22:11:20","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/verrica-pharmaceuticals-reports-third-quarter-2025-financial-results\/"},"modified":"2025-11-14T17:11:20","modified_gmt":"2025-11-14T22:11:20","slug":"verrica-pharmaceuticals-reports-third-quarter-2025-financial-results","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/verrica-pharmaceuticals-reports-third-quarter-2025-financial-results\/","title":{"rendered":"Verrica Pharmaceuticals Reports Third Quarter 2025 Financial Results"},"content":{"rendered":"
\n

\n \u2013<\/em>\u00a0\u00a0 Company reports $14.3 million in revenue in Q3\u201925, consisting of $3.6 million in YCANTH<\/em>\u00ae<\/em><\/sup> revenue and $10.7 million of license and collaboration revenue \u2013<\/em><\/p>\n

\n \u2013 Reports positive feedback from the FDA and alignment regarding the study design of a Phase 3 program for VP-315 in basal cell carcinoma; Company presented new data on VP-315 at the recent Society for Immunotherapy of Cancer conference \u2013<\/em>\n <\/p>\n

\n \u2013 Received positive feedback from European Medicines Agency that supports a Marketing Authorization Application filing for YCANTH for molluscum without need for additional Phase 3 studies \u2013<\/em>\n <\/p>\n

\n \u2013 Received $10 million cash milestone payment for approval of YCANTH for molluscum in Japan \u2013 <\/em>\n <\/p>\n

\n \u2013 Conference call scheduled for Monday, November 17, 2025, at 8:30 am ET \u2013<\/em>\n <\/p>\n

WEST CHESTER, Pa., Nov. 14, 2025 (GLOBE NEWSWIRE) — Verrica Pharmaceuticals Inc. (\u201cVerrica\u201d) (Nasdaq: VRCA), a dermatology therapeutics company developing and selling medications for skin diseases requiring medical interventions, today announced financial results for the third quarter ended September 30, 2025.<\/p>\n

\u201cIn the third quarter, Verrica achieved multiple commercial, corporate, scientific and regulatory milestones providing a strong foundation for future growth in YCANTH as well as significant upside potential from our late-stage clinical pipeline,\u201d said Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica. \u201cThroughout the past year, while growing adoption of YCANTH for molluscum, we have also significantly advanced our late-stage clinical programs in two of the highest unmet needs in dermatology.\u201d<\/p>\n

Dr. Rieger continued, \u201cFor the nine months ending September 30, 2025, we dispensed 37,642 applicator units compared to 17,119 units in the prior year, representing a 120% increase. I commend our team for more than doubling dispensed units of YCANTH over this period while reducing operating expenses by nearly half. We also made three significant advances in our development pipeline over this same period. First, we have begun our global Phase 3 clinical program of YCANTH (VP-102) in common warts with our Japanese development partner, Torii Pharmaceutical, with targeted first patient enrolled in the United States this year. Verrica also helped support Torii in obtaining the approval of YCANTH for molluscum in Japan in September. Second, we recently received European regulatory feedback providing a pathway to registration for YCANTH for molluscum in Europe without the need for additional Phase 3 studies. Finally, we received clear and positive feedback from the FDA about the study design for a Phase 3 development program for our oncology asset, VP-315, for basal cell carcinoma, the most common form of skin cancer. Each of these development opportunities represent meaningful future growth potential for Verrica, and together we believe they compose one of the most advanced portfolios of late-stage product candidates in dermatology.\u201d\u00a0\u00a0<\/p>\n

\u201cRecent interest in Verrica\u2019s pipeline candidates at multiple scientific and business conferences has demonstrated the potential of our portfolio, enabling potential partnering and other non-dilutive financing discussions to help support further development and commercialization efforts for these late-stage programs. I couldn\u2019t be more proud of our simultaneous achievement of these goals, and we are excited to see what\u2019s ahead for Verrica into the end of 2025 and beyond,\u201d concluded Dr. Rieger.<\/p>\n

\n Conference Call and Webcast Information<\/strong>\n <\/p>\n

The Company will host a conference call on Monday, November 17, 2025, at 8:30 am, to discuss its third quarter 2025 financial results and provide a business update. To participate in the conference call, please utilize the following information:<\/p>\n

Domestic Dial-In Number: Toll-Free: 1-800-245-3047
International Dial-In Number: 1-203-518-9765
Conference ID: VERRICA<\/p>\n

Participants can use Guest dial-in #s above and be answered by an operator.<\/p>\n

\n Webcast:<\/strong>\n <\/p>\n

\n https:\/\/viavid.webcasts.com\/starthere.jsp?ei=1736699&tp_key=4cd2293ef2<\/a>\n <\/p>\n

The call will be broadcast live over the Web and can also be accessed on Verrica Pharmaceuticals\u2019 website:\u00a0www.verrica.com<\/a>.\u00a0<\/p>\n

The conference call will also be available for replay for one month on the Company\u2019s website in the Events Calendar of the Investors section.<\/p>\n

\n Business Highlights and Recent Developments<\/strong>\n <\/p>\n

\n YCANTH<\/strong>
\n
\n \u00ae<\/strong>
\n <\/sup>
\n (VP-102) <\/strong>\n <\/p>\n